Lower tumor weights were detected in the shisa3-overexpressing PC9/ER tumors or the PC9/ER tumors with EGFR-TKI (gefitinib/osimertinib) treatment, and even the lowest tumor weights were observed in the shisa3-overexpressing PC9/ER tumors with gefitinib or osimertinib treatment (Fig. 6c). This evidence concerns the gene EGFR and neoplasm.